Antinuclear Antibody

Antinuclear antibodies (ANAs) are a heterogeneous group of autoantibodies that recognize constituents of the cell nucleus, including DNA, nuclear proteins, and nucleic acid–protein complexes. The term denotes many antibody specificities rather than a single antibody. In laboratory practice, ANA testing also detects some antibodies against cytoplasmic and mitotic structures, giving the test a broader scope than its name suggests. (nature.com)

ANAs are important laboratory markers in the evaluation of autoimmune diseases, particularly systemic lupus erythematosus, systemic sclerosis, and Sjögren disease. Their presence alone does not establish a diagnosis: positive results also occur in people without autoimmune disease and in association with some infections, medications, and other conditions. Clinical significance depends on the testing method, antibody specificity, fluorescence pattern, titer, and accompanying clinical findings. (rheumatology.org)

ANA research connects the biology of immune tolerance with clinical laboratory medicine. Particular antibodies can participate in disease mechanisms, whereas others principally serve as markers of an autoimmune response. Understanding ANAs therefore involves their molecular targets and origins, population distribution, detection methods, disease associations, and the limits of interpreting a laboratory result. (nature.com)

Definition and Scope

Antinuclear antibodies (ANAs) are a heterogeneous group of autoantibodies that recognize self-antigens associated with the cell nucleus. Their targets include DNA, proteins associated with chromatin, and protein components of complexes containing RNA. The designation describes what these antibodies recognize, rather than a single antibody molecule or a single nuclear substance. For example, an antibody binding double-stranded DNA and an antibody binding a protein within a nuclear ribonucleoprotein complex both fall within the ANA group, despite recognizing chemically different targets. “Antinuclear” therefore does not mean exclusively “anti-DNA,” nor does it imply that every ANA binds every nuclear component. (pubmed.ncbi.nlm.nih.gov)

The antibody group must be distinguished from the ANA test, a laboratory investigation intended to detect such reactivity. In clinical usage, “ANA” can refer either to antibodies in a serum sample or, more loosely, to the result of an assay. A broad screening result does not necessarily identify the antigen responsible: “ANA positive” is not equivalent to “anti-double-stranded-DNA positive.” Cell-based indirect immunofluorescence surveys binding to structures present in HEp-2 cells, whereas antigen-based immunoassays detect binding to the particular antigens incorporated into the assay. Consequently, the biological category of ANAs and the operational coverage of an individual ANA test are related but not identical; the assay method determines which reactivities can be detected and how they are represented in the report. (arupconsult.com)

The historical expression antinuclear factor (ANF) reflects the earlier description of nuclear-reactive activity as a serum “factor,” before its constituent antibody specificities had been fully differentiated. In 1957, H. R. Holman and H. G. Kunkel reported the affinity of the lupus erythematosus serum factor for cell nuclei and nucleoprotein. Work published that December by W. C. Robbins, Holman, H. Deicher, and Kunkel demonstrated that nuclear and DNA reactivity could be separated: one serum reacted strongly with nuclei but not with DNA, and cross-absorption experiments indicated two distinct serum factors. Thus, the singular historical term does not designate one molecular entity; ANA encompasses multiple antigen-specific antibody populations that may coexist in a sample. (pubmed.ncbi.nlm.nih.gov)

In its strict anatomical sense, ANA denotes nuclear reactivity. HEp-2 testing nevertheless exposes antibodies to cellular compartments beyond the nucleus, so an “ANA report” may contain nuclear, cytoplasmic, and mitotic findings. The 2014–2015 International Consensus on ANA Patterns distinguished these three major categories. Nuclear patterns are defined by staining of interphase nuclei, including nucleoplasm, nucleoli, or the nuclear envelope, whether or not dividing cells also stain. Cytoplasmic patterns involve structures outside the nucleus, such as filament systems, mitochondria, or the Golgi apparatus. Mitotic patterns involve structures associated with cell division, including spindle fibers, centrosomes, or the intercellular bridge. Staining a dividing cell is therefore not, by itself, sufficient to classify a finding as a mitotic pattern. (pmc.ncbi.nlm.nih.gov)

This broader assay scope explains why cytoplasmic or mitotic reactivity can be documented even when nuclear staining is absent. The established name “ANA test” has been retained for historical and laboratory-administrative reasons, although “anti-cell” more closely describes the full range of HEp-2 staining. Reporting conventions are not uniform: the initial international consensus favored reporting clear cytoplasmic or mitotic reactivity as positive, whereas an ARUP testing algorithm distinguishes nuclear-positive results from nuclear-negative samples showing cytoplasmic staining. A statement about nuclear reactivity and a statement about the overall HEp-2 assay result therefore need not express the same finding. (pmc.ncbi.nlm.nih.gov)

Molecular Targets and Antibody Specificities

DNA- and chromatin-directed antibodies recognize several distinct molecular substrates. Anti-double-stranded DNA (anti-dsDNA) antibodies bind DNA, whereas anti-histone antibodies recognize proteins associated with DNA; these specificities are not interchangeable. Anti-nucleosome antibodies can recognize composite epitopes formed by the association of DNA with histones, rather than either isolated component. Consequently, anti-chromatin reactivity need not imply detectable anti-dsDNA reactivity. In a 1994 study of sera from 40 patients with systemic lupus erythematosus, whole chromatin was recognized by 88% of samples; approximately half reacted with chromatin and H2A–H2B–DNA complexes while showing little or no binding to native DNA. Experiments with monoclonal antibodies from lupus-prone mice likewise demonstrated nucleosome-specific recognition that was not reproduced by isolated DNA or individual histones. (pubmed.ncbi.nlm.nih.gov)

RNA-associated targets include the protein components of ribonucleoprotein complexes, not simply RNA itself. The Sm antigen comprises core proteins shared among several small nuclear ribonucleoprotein particles involved in RNA splicing. Anti-Sm antibodies commonly recognize B/B′ and D proteins, whereas anti-U1-RNP antibodies recognize proteins specifically associated with U1 RNA, particularly U1-70K, U1-A, and U1-C. These antibody systems can coexist because U1 particles contain both Sm-core and U1-specific proteins, but they remain molecularly distinguishable. Immunoblotting and immunoprecipitation experiments demonstrated that antibodies purified against Sm B/B′ or D recovered multiple small nuclear RNP particles, while antibodies against U1-70K, A, or C recovered U1 particles specifically. (pubmed.ncbi.nlm.nih.gov)

Extractable nuclear antigens (ENAs) are a laboratory grouping derived from antigens recoverable in saline-soluble cellular extracts, rather than a single molecular family. The designation encompasses structurally and functionally different targets, including Sm, U1-RNP, SSA/Ro, and SSB/La. Panel composition is therefore part of the meaning of an ENA result: the label does not establish that every ANA-associated target has been examined. For example, ARUP Laboratories’ named ENA panel measures Smith/RNP, Smith, SSA-52, SSA-60, and SSB antibodies as separately reported components. (content-assets.jci.org)

SSA/Ro itself comprises two distinct antigenic targets. Ro60 is an approximately 60-kDa RNA-binding protein associated with small noncoding Y RNAs; Ro52, also called TRIM21, is an approximately 52-kDa protein with ubiquitin E3-ligase activity. Anti-Ro52 and anti-Ro60 therefore identify different specificities, despite their shared SSA/Ro designation. SSB/La is a separate RNA-binding antigen that can occur in Y-RNA-containing particles alongside Ro60. Physical association within an RNP does not make anti-La and anti-Ro60 equivalent antibodies. Antigen-specific panels can preserve these distinctions by reporting Ro52, Ro60, and La separately, rather than combining all Ro-associated reactivity into one result. (pmc.ncbi.nlm.nih.gov)

Structural targets include centromere proteins CENP-A, CENP-B, and CENP-C, as well as nuclear-envelope proteins. The latter include lamins and lamin-associated proteins, and components of nuclear pores such as gp210. Other targets combine structural localization with enzymatic function: fibrillarin is a major protein of the nucleolar U3 small nucleolar RNP complex, while DNA topoisomerase I is the antigen identified by the antibody designation anti-Scl-70. These names identify particular proteins or protein complexes, not antibodies against the centromere, nucleolus, or nuclear envelope as undifferentiated structures. (anapatterns.org)

RNA polymerases provide another group of enzymatic targets. Antibodies can recognize polymerases I, II, and III, including multiple constituent subunits. Research published in 1993 identified sera reacting with all three polymerase classes; subsequent subunit analysis demonstrated that some antibodies cross-react with proteins shared between polymerase complexes. Thus, “anti-RNA polymerase” is broader than the specific designation “anti-RNA polymerase III,” and recognition of one polymerase cannot automatically be equated with recognition of the others. (pubmed.ncbi.nlm.nih.gov)

Immunological Formation and Biological Effects

ANA production involves the activation of autoreactive B cells and their differentiation into antibody-secreting plasma cells. Autoreactive cells also occur in healthy individuals; their presence alone does not establish a failure of self-tolerance. Normally, receptor editing, deletion, functional silencing, and restrictions on differentiation limit their contribution to circulating antibodies. These controls can be impaired at different stages in systemic lupus erythematosus (SLE). A 2019 study comparing nine healthy subjects with 15 patients with SLE found that increased numbers of ANA-producing IgG plasmablasts reflected expansion of the overall IgG plasmablast compartment, rather than an increased proportion of nuclear-reactive cells within it. Thus, excessive antibody-producing-cell differentiation can contribute alongside defects in antigen-specific selection. (pmc.ncbi.nlm.nih.gov)

Nuclear targets become accessible when cells die or release intracellular material. During apoptosis, chromatin is fragmented and nuclear constituents redistribute into membrane-bound cellular remnants. In 1994, Livia Casciola-Rosen, Grant Anhalt, and Antony Rosen demonstrated that apoptotic keratinocytes concentrated nucleosomal DNA, Ro, La, and small nuclear ribonucleoproteins in large surface blebs. Their removal by efferocytosis normally limits exposure and suppresses inflammation. Experimental disruption of clearance provides evidence connecting persistent debris with autoimmunity: mice lacking liver X receptors exhibited defective apoptotic-cell engulfment, inappropriate inflammatory responses, autoantibody production, and autoimmune glomerulonephritis. These findings establish mechanisms by which normally sequestered antigens can become immunologically available, without implying that cell death invariably induces ANAs. (pmc.ncbi.nlm.nih.gov)

Once antibodies bind extracellular nuclear material, the resulting immune complexes can couple antigen-specific recognition to innate immune activation. In 2002, Elizabeth Leadbetter and colleagues showed that IgG2a–chromatin complexes activated mouse B cells carrying an IgM receptor directed against IgG. Activation required both the B-cell antigen receptor and a MyD88-dependent Toll-like receptor pathway; inhibitor experiments implicated TLR9. The antigen receptor captures the complex and facilitates intracellular delivery, allowing its nucleic-acid component to reach endosomal sensors. This experimentally demonstrated dual-recognition mechanism explains how a complex containing self-protein and self-DNA can provide complementary activation signals rather than functioning merely as a passive antibody–antigen aggregate. (pubmed.ncbi.nlm.nih.gov)

A related pathway operates in plasmacytoid dendritic cells, which can produce substantial amounts of type I interferon. Human-cell experiments published in 2005 showed that DNA-containing complexes purified from lupus serum entered these cells through FcγRIIa, also called CD32, and activated TLR9-containing intracellular compartments. Separate experiments demonstrated that mammalian DNA- and RNA-containing complexes induced interferon-α through TLR9 and TLR7, respectively; nuclease treatment abolished their stimulatory activity. In 2010, Cristiana Guiducci and colleagues further demonstrated in human cells and lupus-prone mice that TLR7/TLR9 stimulation supported plasmacytoid dendritic-cell survival through NF-κB activation, sustaining the interferon-producing population. Antibody binding therefore can facilitate nucleic-acid delivery and inflammatory signaling, even when the antibody recognizes an associated protein rather than the nucleic acid itself. (pmc.ncbi.nlm.nih.gov)

Human genetics provides an additional causal example. In 2022, Grant Brown and colleagues identified a de novo TLR7 Y264H gain-of-function variant in a child with severe lupus. The altered receptor showed increased sensing of guanosine and 2′,3′-cyclic GMP. Introducing the variant into mice was sufficient to produce lupus-like disease, while enhanced TLR7 signaling promoted abnormal survival of B-cell-receptor-activated cells and accumulation of particular activated B-cell populations. This finding demonstrates that excessive nucleic-acid sensing can drive loss of immune restraint, but does not establish the same genetic cause for all ANA production or all SLE. (researchonline.jcu.edu.au)

Biological effects differ among antibody specificities and individual antibody clones. Some ANAs chiefly serve as markers of an autoimmune response; detecting them does not demonstrate direct tissue injury. Certain anti-DNA or anti-chromatin antibodies can participate in complexes that accumulate in renal structures, activate the complement system, and engage Fc receptors on inflammatory cells. Other nucleic-acid-containing complexes exert effects through cytokine induction rather than deposition. Pathogenicity consequently depends on antigen availability, binding characteristics, antibody isotype, clearance, and tissue context—not simply on recognition of a nuclear antigen. The evidence for these mechanisms cannot be extended uniformly to every antibody included under ANA. (nature.com)

Historical Discovery and Development

In 1948, Malcolm M. Hargraves, Helen Richmond, and Robert Morton reported the lupus erythematosus (LE) cell in bone-marrow preparations at the Mayo Clinic. Their paper distinguished it from the “tart” cell, another cell containing ingested nuclear material. The characteristic LE cell is a neutrophil that has engulfed altered nuclear material from another cell; this material forms a homogeneous inclusion rather than retaining a recognizable nuclear structure. In 1949, Hargraves demonstrated that the phenomenon could be produced in vitro using normal bone-marrow elements and plasma from patients with acute disseminated lupus erythematosus. This made the observation reproducible as a laboratory reaction and provided an early laboratory aid to investigating systemic lupus erythematosus, rather than merely a descriptive finding in marrow smears. (pubmed.ncbi.nlm.nih.gov)

The ability of patients’ plasma to induce LE-cell formation directed investigation toward a circulating factor acting on nuclear material. On July 26, 1957, Halsted R. Holman and Henry G. Kunkel published Affinity between the Lupus Erythematosus Serum Factor and Cell Nuclei and Nucleoprotein, connecting the LE phenomenon with serum reactivity against nuclear constituents. Subsequent experiments distinguished this activity from antibodies directed against DNA itself. In December 1957, William C. Robbins, Holman, Herbert Deicher, and Kunkel reported that lupus sera could fix complement with isolated nuclei, nucleoprotein, and purified DNA. Absorption experiments supported the presence of separate nuclear-reactive and DNA-reactive factors; one serum reacted strongly with nuclei but not with DNA. These findings established that nuclear reactivity comprised multiple antibody activities, not a single universal “LE factor.” (pubmed.ncbi.nlm.nih.gov)

A parallel development was the visualization of nuclear-reactive serum factors by immunofluorescence. In September 1957, Eric J. Holborow, D. M. Weir, and G. D. Johnson published their demonstration of a lupus serum factor with affinity for tissue nuclei. Fluorescent detection allowed laboratories to observe serum-antibody binding without requiring the completion of nuclear alteration and phagocytosis necessary for LE-cell formation. Immunofluorescence progressively displaced the more time-consuming LE-cell preparation: by 1979, Holborow described its substitution as widespread. The broader detection also revealed nuclear reactivity in patients without lupus and in some healthy individuals, making the distinction between an antibody-screening result and a disease-specific finding increasingly important. (bmj.com)

During the following decades, investigators separated antigen-specific systems within the broad ANA reaction. Historical milestones included DNA-reactive antibodies in 1957, histone-reactive antibodies in 1959, the Sm system described by Eng M. Tan and Kunkel in 1966, and ribonucleoprotein-reactive antibodies in 1971. Precipitation and other antigen-based experiments differentiated these reactions more precisely than staining morphology alone. Holborow’s 1979 account consequently treated immunofluorescence as a screening procedure whose positive results could be investigated with tests against identified nuclear antigens, rather than assuming that each fluorescence pattern uniquely specified an antibody. (jcp.bmj.com)

International standardization of the visual vocabulary became a separate undertaking in 2014. The International Consensus on ANA Patterns (ICAP) began with a full-day session on August 28 at the 12th International Workshop on Autoantibodies and Autoimmunity in São Paulo, Brazil. Edward K. L. Chan, Jan Damoiseaux, Luis E. C. Andrade, and their collaborators published the first nomenclature report on August 20, 2015. Its classification organized 28 patterns, coded AC-1 through AC-28, into nuclear, cytoplasmic, and mitotic groups. It also distinguished “competent-level” patterns recommended for routine reporting from “expert-level” patterns requiring more specialized recognition, and supplied representative images through the ICAP website to harmonize terminology across laboratories. (pubmed.ncbi.nlm.nih.gov)

Population Distribution and Positivity Outside Systemic Autoimmune Disease

A 2012 study by Minoru Satoh and colleagues estimated ANA prevalence using serum samples from 4,754 participants in the United States National Health and Nutrition Examination Survey (NHANES), collected during 1999–2004. The estimated prevalence among people aged 12 years or older was 13.8%, with a 95% confidence interval of 12.2–15.5%. Testing used indirect immunofluorescence on HEp-2 cells at a serum dilution of 1:80; fluorescence intensity was graded on a 0–4 scale, with grades 3 and 4 classified as positive. The estimate therefore describes positivity under a specified laboratory protocol in a population survey, rather than the proportion of people with diagnosed systemic autoimmune disease. (pubmed.ncbi.nlm.nih.gov)

ANA prevalence differed by age and sex in this analysis. Positivity was estimated at 17.8% in females and 9.6% in males, a statistically significant difference ($P<0.001$); the female-to-male prevalence ratio was greatest at ages 40–49. Prevalence also increased with age overall ($P=0.01$). These were cross-sectional associations: the study did not establish that aging or a particular hormonal mechanism caused ANA production, nor did it follow individuals to determine when their antibodies first appeared. Its participants represented a general population sample, not a cohort selected exclusively for apparent health or for rheumatic disease. (pubmed.ncbi.nlm.nih.gov)

Positivity also occurs in apparently healthy individuals, and its measured frequency depends strongly on the threshold used. In a 1997 international study led by Eng M. Tan, involving 15 laboratories, healthy participants were ANA-positive in 31.7% of cases at a dilution of 1:40, 13.3% at 1:80, 5.0% at 1:160, and 3.3% at 1:320. Thus, requiring detectable staining at greater dilution substantially reduced the proportion classified as positive. That study found no significant age differences within its four adult age groups spanning 20–60 years, illustrating that age findings also depend on the sampled age range and population. The American College of Rheumatology states that up to 15% of completely healthy people may have a positive ANA result. These figures are not universal constants: assay procedures, positivity thresholds, and participant selection all affect the observed frequency. (pubmed.ncbi.nlm.nih.gov)

Viral infections provide documented examples of ANA positivity outside systemic autoimmune rheumatic disease. A 2011 study by Yeon Seok Seo and colleagues examined 422 patients hospitalized with acute hepatitis A, defining positivity as a titer of at least 1:80. ANA was detected in 179 patients (42.4%), with positivity substantially more frequent during the icteric or recovery period than during the prodromal period. The investigators reported that ANA became undetectable within three months in the ANA-positive patients, and found no significant difference in complication rates between positive and negative groups. This infection-associated, transient reactivity was therefore distinct from evidence establishing a persistent systemic autoimmune disease. (pubmed.ncbi.nlm.nih.gov)

Medication exposure can likewise produce ANA without necessarily producing a clinical autoimmune syndrome. In a prospective study published in 1969, Stephen E. Blomgren and colleagues followed 16 patients receiving procainamide for cardiac arrhythmias: eight developed ANA, but only two of those eight developed symptoms consistent with a lupus syndrome. This separates drug-associated antibody formation from symptomatic drug-induced disease and from idiopathic systemic lupus erythematosus. Malignancy is another recognized setting in which ANA positivity may occur; the American College of Rheumatology lists cancer, medications, and viruses among conditions associated with positive results. In these settings, antibody detection is a laboratory observation rather than, by itself, a diagnosis of systemic autoimmune rheumatic disease. (nejm.org)

Laboratory Detection Methods

Indirect immunofluorescence (IIF, also called IFA) detects serum antibodies binding to fixed HEp-2 cells on a microscope slide. Diluted serum is incubated with the cellular substrate, allowing antibodies to bind accessible intracellular antigens. Washing removes unbound serum components; a fluorescein-labelled anti-human IgG reagent is then added to detect the bound human antibodies. After another wash, the slide is examined with a fluorescence microscope. The method is “indirect” because the fluorescent label is attached to the detection reagent rather than to the patient’s antibodies. A published 2014 protocol used a 30-minute incubation with the fluorescent conjugate, although operating conditions depend on the validated assay. (pmc.ncbi.nlm.nih.gov)

HEp-2 cells provide a broad cellular antigen repertoire rather than a predetermined list of purified targets. Microscopic assessment establishes whether staining is present and describes its distribution across nuclear, cytoplasmic, and mitotic structures; examination of dividing cells supplies information unavailable from interphase nuclei alone. Positive specimens can undergo further dilution to determine an endpoint titer. This combination of broad antigen coverage and spatial information makes HEp-2 IIF an important screening method, but the staining distribution does not, by itself, identify the molecular target. The International Consensus on ANA Patterns report published in 2015 standardized the terminology used to describe these distributions. (pmc.ncbi.nlm.nih.gov)

Antigen-based assays instead measure antibody binding to preparations immobilized on plates, beads, or membranes. In an enzyme-linked immunosorbent assay (ELISA), serum antibodies bind the coated antigens, an enzyme-labelled anti-human IgG reagent detects bound antibody, and addition of an enzyme substrate produces a signal measured by a plate reader. Some ANA ELISAs use cellular extracts supplemented with purified antigens rather than exclusively defined antigen mixtures. For example, a Mayo Clinic Laboratories assay uses HEp-2 lysate supplemented with double-stranded DNA, histones, SSA/Ro, SSB/La, Sm, Sm/RNP, Scl-70, Jo-1, and centromere B antigen. Chemiluminescence assays use light-generating detection chemistry, while multiplex bead and line immunoassays can distinguish responses to several separately presented targets. Their coverage therefore depends on which antigens are included and how those antigens are prepared and presented. (prd1.mayocliniclabs.com)

The methods differ in analytical coverage and workflow. HEp-2 IIF generally offers high screening sensitivity but is labor-intensive and requires expertise in recognizing weak or overlapping staining. Antigen-based systems support automation, higher throughput, and more objective signal measurement; restricted antigen repertoires can increase diagnostic specificity while missing antibodies directed against omitted targets. These are general tendencies, not fixed properties of every commercial assay: performance varies by platform and disease. Consequently, an IIF-positive specimen can be negative on an antigen panel, and an antigen-specific assay can detect reactivity not evident by IIF. Results from the two approaches are not interchangeable measurements of a single antibody quantity. (arupconsult.com)

Antigen-specific follow-up testing answers a narrower question than broad ANA screening: whether antibodies against a particular target are detectable. Laboratories may investigate anti-dsDNA or selected extractable nuclear antigen antibodies, including anti-Sm, anti-U1-RNP, anti-SSA/Ro, and anti-SSB/La, using individual assays or panels. As a concrete example, ARUP’s first-line connective tissue disease panel includes dsDNA, Smith/RNP, Smith, SSA-52, SSA-60, SSB, Jo-1, and Scl-70. Identifying one of these specificities characterizes part of the serum’s reactivity; it does not reproduce the full HEp-2 screen. Conversely, a negative panel excludes only detectable reactivity to its included targets, not every antibody capable of staining HEp-2 cells. (arupconsult.com)

Immunofluorescence Patterns

The International Consensus on ANA Patterns (ICAP) assigns AC, meaning anti-cell, codes to recognizable staining distributions in HEp-2 indirect immunofluorescence. Its first nomenclature report, published in 2015 by Edward K. L. Chan and colleagues, organized patterns into nuclear, cytoplasmic, and mitotic groups. Recognition depends on comparing interphase cells with dividing cells: the distribution of fluorescence within the nucleus, staining or sparing of condensed chromatin, and labeling of the mitotic apparatus help distinguish otherwise similar appearances. An AC code identifies a morphological pattern rather than a particular autoantibody. (frontiersin.org)

Homogeneous nuclear staining (AC-1) is smooth and uniform across the nucleoplasm, with intense, similarly homogeneous staining of condensed chromatin in mitotic cells. Dense fine speckled staining (AC-2) instead contains speckles varying in size, brightness, and density, producing denser and sparser areas within individual interphase nuclei; the metaphase plate also shows strong speckled fluorescence. Centromere staining (AC-3) consists of approximately 40–80 discrete dots per interphase nucleus, which align with the mitotic chromosome mass. This redistribution distinguishes centromere reactivity from nuclear-dot patterns whose targets are not associated with condensed chromosomes. (anapatterns.org)

Fine speckled nuclear staining (AC-4) comprises numerous tiny speckles throughout the nucleoplasm, whereas large/coarse speckled staining (AC-5) has larger, more conspicuous granules. In both, condensed mitotic chromatin is ordinarily unstained; nucleolar staining may vary. AC-4 can accompany antibodies to SSA/Ro or SSB/La, while AC-5 can accompany anti-Sm or anti-U1-RNP antibodies. These are associations, not one-to-one identifications. Likewise, AC-2 is associated with anti-DFS70 antibodies, but visually similar “DFS-like” specimens can be negative in DFS70-specific immunoassays. Pattern recognition therefore cannot substitute for direct determination of antigen specificity. (anapatterns.org)

Nucleolar patterns distinguish fluorescence concentrated in the nucleolus from staining of the surrounding nucleoplasm. Homogeneous nucleolar staining (AC-8) fills nucleoli diffusely while leaving the metaphase plate unstained; associated targets include PM/Scl and Th/To. Clumpy nucleolar staining (AC-9) produces irregular nucleolar masses, sometimes accompanied by Cajal-body and perichromosomal staining, and is associated with fibrillarin. Punctate nucleolar staining (AC-10) consists of distinct nucleolar grains; mitotic cells can display up to five bright pairs of nucleolar organizer regions within the chromosome mass. NOR-90 and RNA polymerase I are associated targets. (frontiersin.org)

Discrete nuclear dots and peripheral nuclear staining form additional groups. Multiple nuclear dots (AC-6) typically number 6–20 per nucleus and include reactivity associated with Sp100-containing nuclear bodies. Few nuclear dots (AC-7) usually number 1–6 and can label Cajal bodies through antibodies to p80-coilin. Smooth nuclear-envelope staining (AC-11) emphasizes a continuous peripheral rim, whereas punctate nuclear-envelope staining (AC-12) produces a dotted outline reflecting nuclear-pore-associated targets. Lamin B and gp210, respectively, are representative antigen associations; neither envelope pattern stains metaphase or anaphase chromatin plates. (anapatterns.org)

ICAP distinguishes multiple, mixed, and composite patterns. Multiple patterns are two or more separately recognizable patterns in one specimen. Mixed patterns overlap within the same cellular compartment so that their components cannot be reliably separated—for example, overlapping AC-4 and AC-5 nuclear speckling. A composite pattern arises when one antibody specificity produces a characteristic combination of staining in different compartments. The NuMA-like pattern, AC-26, combines interphase nuclear speckles with mitotic spindle-fiber staining. Thus, fluorescence in several locations does not necessarily indicate several antibody specificities, and an unresolved mixed appearance does not establish which antibodies are present. Antigen-specific assays provide evidence distinct from the morphological classification. (anapatterns.org)

Titers, Thresholds, and Laboratory Reporting

An indirect immunofluorescence (IIF) titer is the highest serum dilution at which specific staining remains detectable under the assay’s reading criteria. Positive specimens are commonly tested through twofold serial dilutions, such as 1:80, 1:160, 1:320, and 1:640. A dilution of 1:80 contains one part serum in 80 parts total mixture; 1:160 contains half as much serum per unit volume. If recognizable staining persists at 1:160 but disappears at 1:320, the endpoint is reported as 1:160. Thus, a larger denominator represents reactivity persisting at greater dilution, not a weaker result. The titer is a semiquantitative measure of detectable autoantibody reactivity, rather than an absolute antibody concentration. (accessdata.fda.gov)

Fluorescence intensity, endpoint titer, and numerical immunoassay results describe different measurements. Intensity records the brightness of staining at a specified dilution, whereas an endpoint titer records how far the specimen can be diluted before recognizable staining is lost. Automated systems may estimate endpoints from intensity using pattern-specific relationships, but an estimated endpoint is not identical to one measured by serial dilution. A study published in 2020 found that single-dilution intensity-based predictions frequently differed from measured endpoints by more than one dilution step. Alternative immunoassays may express reactivity in arbitrary units; their antigen coverage and calibration differ from those of cell-based IIF. Consequently, an immunoassay number cannot be directly converted into an IIF titer, and brightness at one dilution cannot be treated as the titer itself. (academic.oup.com)

Laboratory thresholds are not uniform. The initial screening dilution determines the lowest level of reactivity that can be detected in a particular workflow, while the laboratory’s reporting cutoff determines which results receive a positive designation. The American College of Rheumatology notes that some laboratories report titers above 1:160 as positive. A laboratory survey published in 2025 documented substantial variation: among 298 laboratories specifying their screening dilution, 199 (67%) used 1:80, 46 (15%) used 1:160, and 26 (9%) used 1:40. These are screening practices, not interchangeable diagnostic thresholds. A negative result at a screening dilution of 1:160 therefore does not establish that the serum would show no staining at 1:80. (rheumatology.org)

An informative IIF report identifies the assay method and cellular substrate, gives the qualitative result, and records the observed pattern or patterns with their respective titers. For example, “HEp-2 IIF: positive; centromere pattern, 1:1280; nuclear homogeneous pattern, 1:80” preserves information that a single “ANA positive” designation would omit. When antigen-specific testing has been performed, the identified antigen specificity is a separate finding: a morphological pattern may suggest a target but does not establish the corresponding antibody’s identity. Reports from antigen-based assays instead identify the assay and numerical or qualitative result rather than assigning a cell-staining pattern. (arupconsult.com)

The International Consensus on ANA Patterns (ICAP) standardizes pattern terminology through named patterns and anticellular, or AC, codes. This standardization does not eliminate ambiguity in the word “negative.” The 2016 ICAP reporting discussion presented two conventions: one counted cytoplasmic and mitotic staining as ANA positivity, whereas the other reserved positivity for nuclear staining. Both retained the nonnuclear pattern and its titer in the report. A specimen lacking detectable nuclear staining can therefore still show cytoplasmic or mitotic reactivity; “nuclear negative” is not equivalent to an absence of all cellular staining. (anapatterns.org)

Associations with Specific Diseases

In systemic lupus erythematosus (SLE), broad ANA positivity and antigen-specific findings convey different information: ANA reactivity occurs across several diseases, whereas anti-double-stranded DNA (anti-dsDNA) and anti-Smith (anti-Sm) antibodies are more specifically associated with lupus. The 2019 EULAR/ACR classification criteria distinguish these SLE-specific antibodies from the general ANA result and require qualifying anti-dsDNA assays to demonstrate at least 90% specificity against relevant disease controls. Neither specificity is present in every patient. In a 2017 study involving 232 patients with SLE, 360 patients with other rheumatic diseases, and 400 healthy donors, anti-Sm testing had 25.9% sensitivity at a threshold selected to yield 99% specificity; anti-dsDNA testing had 30.2% sensitivity at its corresponding 99%-specificity threshold. These figures describe particular assays and cutoffs, not universal detection rates. (arupconsult.com)

Anti-SSA/Ro and anti-SSB/La occur in both Sjögren disease and SLE, so neither constitutes an exclusive disease label. SSA testing may distinguish reactivity against Ro52 and Ro60, which are separate antigenic targets. Anti-SSA antibodies are found in approximately two-thirds of patients with Sjögren disease; anti-SSB is another associated specificity, but the classification framework assigns antibody weight to anti-SSA rather than to isolated anti-SSB positivity. These findings accompany a disease characterized by lymphocytic infiltration of exocrine glands, often producing ocular and oral dryness. Their occurrence in lupus illustrates how an antibody system can be shared between clinically distinct autoimmune diseases. (arupconsult.com)

Anti-U1 ribonucleoprotein (U1-RNP) antibodies are a characteristic serological finding in mixed connective tissue disease (MCTD), whose clinical manifestations combine features encountered in lupus, systemic sclerosis, and inflammatory myopathy. Major MCTD criteria sets incorporate U1-RNP reactivity, but this antibody also occurs in SLE and overlap syndromes. Associated manifestations can include Raynaud phenomenon, swollen fingers, arthritis, and myositis; pulmonary hypertension and interstitial lung disease are important organ associations. U1-RNP-related overlap myositis may combine muscle weakness with scleroderma or lupus features. Anti-U1-RNP is therefore distinct in clinical meaning from anti-Sm, despite the relationship between their ribonucleoprotein targets and their inclusion in overlapping laboratory panels. (arupconsult.com)

In systemic sclerosis, approximately 95% of patients have ANAs, but individual specificities identify different clinical subsets. Anticentromere antibodies are associated predominantly with limited cutaneous disease, including the constellation historically called CREST: calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia. Anti-topoisomerase I, also called anti-Scl-70, and anti-RNA polymerase III are more common in diffuse cutaneous disease. Anti-RNA polymerase III has a particularly established association with scleroderma renal crisis. More than half of patients have one of these three major specificities, which generally occur separately. Their associations describe antibody-defined subsets rather than a uniform systemic-sclerosis phenotype or an inevitable clinical course. (arupconsult.com)

Inflammatory myopathies encompass both nuclear and cytoplasmic antibody systems. Anti-Mi-2 is associated with dermatomyositis and its characteristic skin manifestations, whereas anti-PM/Scl is associated with myositis–systemic-sclerosis overlap. Cytoplasmic targets include aminoacyl-transfer-RNA synthetases, represented by anti-Jo-1, anti-PL-7, and anti-PL-12, and the signal recognition particle, represented by anti-SRP. Antisynthetase antibodies are associated with combinations of muscle inflammation, interstitial lung disease, arthritis, Raynaud phenomenon, and “mechanic’s hands”; anti-SRP is associated with immune-mediated necrotizing myopathy. Thus, a specimen without nuclear staining can still contain clinically relevant myositis-associated autoantibodies and display cytoplasmic reactivity. (arupconsult.com)

Autoimmune liver diseases likewise require separation of nuclear from nonnuclear specificities. ANA and smooth-muscle antibodies characterize type 1 autoimmune hepatitis, whereas liver–kidney microsomal and liver-cytosol antibodies characterize type 2. In primary biliary cholangitis, anti-Sp100 and anti-gp210 are associated nuclear specificities; gp210 reactivity may produce nuclear-envelope staining. Antimitochondrial antibodies instead produce a cytoplasmic reticular pattern and are strongly associated with primary biliary cholangitis. This distinction explains why relevant liver-disease serology may be present even when the nuclear component of an ANA examination is negative. (aasld.org)

Clinical Interpretation and Classification

ANA results modify the probability of disease rather than establish a diagnosis independently. Sensitivity describes how often a test is positive in people with the target disease; specificity describes how often it is negative in those without it. Positive predictive value instead concerns the proportion of positive results that represent that disease, and depends strongly on pretest probability—the likelihood estimated before testing from the clinical setting, history, and examination. Consequently, ANA positivity has different significance in an asymptomatic person and in someone with characteristic multisystem findings. ANA assays can detect genuine antibodies in people without systemic autoimmune rheumatic disease: such findings are not necessarily analytical errors, but have limited diagnostic specificity. A negative result reduces the likelihood of ANA-associated disease, particularly lupus, without universally excluding autoimmune disease; interpretation also depends on the assay’s antigen coverage and sensitivity. (meridian.allenpress.com)

Clinical context includes the nature and distribution of symptoms, objective examination findings, medication exposure, and other laboratory abnormalities. Photosensitive rash, inflammatory joint involvement, cytopenias, and urinary protein or cellular casts provide a different context from isolated nonspecific symptoms. In suspected systemic lupus erythematosus (SLE), evidence may include antigen-specific antibodies, blood counts, urinary findings, and reduced C3 or C4 complement concentrations. These observations are assessed together, including whether another condition better explains them. The ANA method, titer, and staining pattern supply additional information, but neither a pattern nor a high titer substitutes for clinical findings. Conversely, negative broad ANA screening does not necessarily exclude individual disease-associated antibodies. (arupconsult.com)

The 2019 EULAR/ACR lupus classification criteria, published by Martin Aringer and colleagues, require ANA positivity at least once at a titer of $1:80$ or greater on HEp-2 cells, or an equivalent positive test, as an obligatory entry criterion. The equivalent-test provision encompasses a solid-phase ANA screening immunoassay with at least equivalent performance. This requirement reflects ANA’s high sensitivity for SLE: the supporting systematic review included 13,080 patients from 64 studies and estimated sensitivity at this threshold as 97.8%, with a 95% confidence interval of 96.8–98.5%. These figures describe detection among patients with SLE, not the probability that an ANA-positive person has lupus. (acrjournals.onlinelibrary.wiley.com)

Meeting the entry criterion alone is insufficient for classification and contributes no points to the subsequent score. Classification requires at least one clinical criterion and a total of at least 10 points from weighted criteria organized into seven clinical and three immunologic domains. Only the highest-scoring item within each domain counts, and a manifestation is counted only when no more likely explanation exists. For example, anti-Sm and qualifying anti-dsDNA antibodies belong to the same domain; their six-point weights are not added together. The criteria standardize research populations rather than define every clinical presentation. Persistently ANA-negative patients cannot be classified using this framework, but that restriction is not a universal rule excluding a clinical diagnosis of SLE. (pmc.ncbi.nlm.nih.gov)

Broad ANA titers also differ from antigen-specific biomarker measurements used in disease assessment. Changes in overall fluorescence titer cannot identify which antibody population has changed. Anti-DNA concentrations can fluctuate substantially and may track lupus activity, whereas antibodies to RNA-binding proteins have often been described as relatively stable. That contrast is not absolute: a longitudinal study published in 2025 found that anti-Sm/RNP antibodies could fluctuate alongside anti-dsDNA, while anti-SSA showed different dynamics. Thus, antigen-specific results retain distinct meanings; neither a broad ANA titer nor an individual antibody concentration is an interchangeable measure of clinical activity or organ injury. (pmc.ncbi.nlm.nih.gov)

References

1. New insights into the role of antinuclear antibodies in systemic lupus erythematosuspubmed.ncbi.nlm.nih.gov
2. Connective Tissue Diseases - Systemic Autoimmune Rheumatic Diseases | Choose the Right Testarupconsult.com
3. Affinity between the lupus erythematosus serum factor and cell nuclei and nucleoproteinpubmed.ncbi.nlm.nih.gov
4. Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014–2015pmc.ncbi.nlm.nih.gov
5. Antinuclear Antibody Disease Testingarupconsult.com
6. The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosuspubmed.ncbi.nlm.nih.gov
7. Specificity of monoclonal anti-nucleosome auto-antibodies derived from lupus micepubmed.ncbi.nlm.nih.gov
8. Further characterization and subcellular localization of Sm and U1 ribonucleoprotein antigenspubmed.ncbi.nlm.nih.gov
9. Extractable Nuclear Antigen Antibodies (Smith/RNP, Smith, SSA 52, SSA 60, and SSB)ltd.aruplab.com
10. Ribonucleoprotein Particles Containing Non-Coding Y RNAs, Ro60, La and Nucleolin Are Not Required for Y RNA Function in DNA Replicationpmc.ncbi.nlm.nih.gov
11. Anti-Ro52 Autoantibodies from Patients with Sjögren's Syndrome Inhibit the Ro52 E3 Ligase Activity by Blocking the E3/E2 Interfacepmc.ncbi.nlm.nih.gov
12. ANA Patterns: AC-3—Centromereanapatterns.org
13. ANA Patterns: AC-11—Smooth nuclear envelopeanapatterns.org
14. ANA Patterns: AC-9—Clumpy nucleolaranapatterns.org
15. ANA Patterns: AC-29—DNA topoisomerase I (topo I)-likeanapatterns.org
16. Loss of an IgG plasma cell checkpoint in lupuspmc.ncbi.nlm.nih.gov
17. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytespmc.ncbi.nlm.nih.gov
18. Apoptotic cells promote their own clearance and immune tolerance through activation of LXRpmc.ncbi.nlm.nih.gov
19. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptorspubmed.ncbi.nlm.nih.gov
20. Human lupus autoantibody–DNA complexes activate DCs through cooperation of CD32 and TLR9pmc.ncbi.nlm.nih.gov
21. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosuspmc.ncbi.nlm.nih.gov
22. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupusnature.com
23. TLR7 gain-of-function genetic variation causes human lupusresearchonline.jcu.edu.au
24. New insights into the role of antinuclear antibodies in systemic lupus erythematosusnature.com
25. Presentation of two bone marrow elements; the tart cell and the L.E. cellpubmed.ncbi.nlm.nih.gov
26. Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014–2015pubmed.ncbi.nlm.nih.gov
27. Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014–2015frontiersin.org
28. Prevalence and sociodemographic correlates of antinuclear antibodies in the United Statespubmed.ncbi.nlm.nih.gov
29. Prevalence and Sociodemographic Correlates of Antinuclear Antibodies In the United Statespmc.ncbi.nlm.nih.gov
30. Range of antinuclear antibodies in "healthy" individualspubmed.ncbi.nlm.nih.gov
31. Antinuclear Antibodies (ANA) | American College of Rheumatologyrheumatology.org
32. Clinical significance of the detection of antinuclear antibodies in patients with acute hepatitis a.pubmed.ncbi.nlm.nih.gov
33. Clinical Significance of the Detection of Antinuclear Antibodies in Patients with Acute Hepatitis Apmc.ncbi.nlm.nih.gov
34. Anti-Nuclear Antibody Screening Using HEp-2 Cellspmc.ncbi.nlm.nih.gov
35. Connective Tissue Diseases - Systemic Autoimmune Rheumatic Diseasesarupconsult.com
36. Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014–2015frontiersin.org
37. ANA Patterns — Nuclear Patternsanapatterns.org
38. ANA Patterns — Frequently Asked Questionsanapatterns.org
39. ANA Patterns — Search Results for numaanapatterns.org
40. Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspectivepmc.ncbi.nlm.nih.gov
41. International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA resultsanapatterns.org
42. REVIEW MEMORANDUMaccessdata.fda.gov
43. FDA Decision Summary: K150155accessdata.fda.gov
44. What is the clinical significance of anti-Sm antibodies in systemic lupus erythematosus? A comparison with anti-dsDNA antibodies and C3pubmed.ncbi.nlm.nih.gov
45. Sjögren Syndromearupconsult.com
46. Mixed Connective Tissue Disease - MCTDarupconsult.com
47. Association of Combined Autoreactivity to Sm/RNP Common Motif and U1 RNP With Mixed Connective Tissue Disease and Systemic Lupus Erythematosuspmc.ncbi.nlm.nih.gov
48. Systemic Sclerosis - Sclerodermaarupconsult.com
49. Anti-RNA polymerase III antibodies in patients with suspected and definite systemic sclerosis: Why and how to screenpmc.ncbi.nlm.nih.gov
50. Inflammatory Myopathiesarupconsult.com
51. Back to Basics: ANA-lyzing Autoimmune Hepatitisaasld.org
52. Autoimmune Liver Disease Testingarupconsult.com
53. ANA Patterns: AC-12anapatterns.org
54. 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosuspmc.ncbi.nlm.nih.gov
55. Differences in Dynamics of Specific Antinuclear Antibodies and Their Susceptibility to B Cell–Targeting Treatment in Patients With Systemic Lupus Erythematosuspmc.ncbi.nlm.nih.gov